My system is made of a protein that binds to the membrane, which carries the epitope tag, and a nanobody, binding this tag. Membrane binding protein is a fusion protein consisting of a protein fluorophore mNeonGreen and a membrane-binding domain. The nanobody is labeled with Cy5 maleimide. Separately, both protein and nanobody work well in other systems. However, the addition of nanobody to the wells with protein bound on cell membrane leads to a drop in fluorescence in the FITC channel by order of magnitude. I suggest that this phenomenon may be either due to the unbinding of the whole protein complex from the membrane following nanobody binding to epitope tag or due to the mNeonGreen fluorescence quenching (however, as far as I know Cy5 does not quench mNeonGreen). I feel stuck as I don't know how to design a workflow to distinguish between the two.

If anyone has some experience in the field and can share an idea or outline the direction, any advice would be deeply appreciated.

More Ekaterina M. Koltsova's questions See All
Similar questions and discussions